Corticosteroid 11 beta dehydrogenase isozyme 1

LABA+ICS群と比較し、LAMA+LABA群の統合された主要評価項目の結果は以下の通りである:増悪、OR (95%CI ~、P = 、I 2 = 17%、低い質のエビデンス);重篤な副作用、(95%CI ~、P = 、I 2 = 0%、中等度の質のエビデンス);St. George's Respiratory Questionnaire (SGRQ)ベースラインからの変化、MD -(95%CI ~、P = 、I 2 = 71%、低い質のエビデンス);トラフ一秒量ベースラインからの変化、MD (95%CI ~、P <、I 2 = 50%、中程度の質のエビデンス)。同様に二次評価項目の結果は以下の通りである:肺炎、OR (95%CI ~、P = 、I 2 = 0%、低い質のエビデンス);全死亡、OR (95%CI ~、P = 、I 2 = 0%、低い質のエビデンス)、臨床的有意な最小変化量(4点)以上のSGRQベースラインからの改善、OR (95%CI ~、P = 、I 2 = 0%、中等度の質のエビデンス)。

Patients requiring oral corticosteroids should be weaned slowly from systemic corticosteroid use after transferring to Advair Diskus. Prednisone reduction can be accomplished by reducing the daily prednisone dose by mg on a weekly basis during therapy with Advair Diskus. Lung function (mean forced expiratory volume in 1 second [FEV 1 ] or morning peak expiratory flow [AM PEF]), beta-agonist use, and asthma symptoms should be carefully monitored during withdrawal of oral corticosteroids. In addition, patients should be observed for signs and symptoms of adrenal insufficiency, such as fatigue, lassitude, weakness, nausea and vomiting, and hypotension.

Corticosteroid 11 beta dehydrogenase isozyme 1

corticosteroid 11 beta dehydrogenase isozyme 1

Media:

corticosteroid 11 beta dehydrogenase isozyme 1corticosteroid 11 beta dehydrogenase isozyme 1corticosteroid 11 beta dehydrogenase isozyme 1corticosteroid 11 beta dehydrogenase isozyme 1corticosteroid 11 beta dehydrogenase isozyme 1

http://buy-steroids.org